+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Remission induction treatment in adults with acute myeloid leukemia. 8-year experience with 2 successive protocols



Remission induction treatment in adults with acute myeloid leukemia. 8-year experience with 2 successive protocols



Medicina Clinica 92(16): 601-604



We report our eight year experience remission induction therapy in adult patients with acute myeloblastic leukemia. Overall 67 patients were treated, with a mean age of 43.3 years (range 15-75). Two treatment protocols were used. Complete remission (CR) was achieved in 23 patients of 39 receiving protocol A (58%). The 28 last patients were treated with the more aggressive protocol B, and CR was achieved in 23 patients (82%). CR was achieved in 68% of the overall group. The most outstanding predictive factors were age above 30 years, and M-5 morphology as indicating a poor prognosis.

(PDF emailed within 1 workday: $29.90)

Accession: 041229915

Download citation: RISBibTeXText

PMID: 2747321


Related references

The role of allogeneic bone marrow transplantation in the younger adults with acute myeloid leukemia in first remission A ten-year experience of the BGMT group. Blood 88(10 SUPPL 1 PART 1-2): 683A, 1996

A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 90(12): 4710-4718, 1998

Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. Cancer 110(8): 1752-1759, 2007

Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 116(1): 93-97, 2010

Idarubicin for remission induction of acute myeloid leukemia: United Kingdom multicenter experience. Seminars in Oncology 20(6 Suppl 8): 13-19, 1993

Therapy for acute myeloid leukemia in 119 adults: a comparison of two treatment protocols. Blut 51(1): 49-56, 1985

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109(12): 5129-5135, 2007

GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia. Blood 84(10 SUPPL 1): 231A, 1994

Treatment failure in children with acute myelocytic leukemia: over 25-year experience of Polish Pediatric Leukemia/Lymphoma Study Group with four consecutive unified treatment protocols for childhood acute myelocytic leukemia. Przeglad Lekarski 67(6): 366-370, 2011

Autologous bone marrow transplantation using 4-hydroperoxycyclophosphamide purging for acute myeloid leukemia beyond first remission A ten year experience. Blood 92(10 SUPPL 1 PART 1-2): 323A, Nov 15, 1998

The time interval from diagnosis of acute myeloid leukemia in older adults to start of remission induction therapy predicts survival. Blood 102(11): 875a, November 16, 2003

Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. Leukemia Research 38(8): 901-906, 2014

Long-Term Survival from a Phase 3 Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults with De Novo Acute Myeloid Leukemia. Blood 100(11): Abstract No 1325, November 16, 2002

Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: The pathogenetic role of the antileukemic regimen. Clinical Infectious Diseases 21(2): 361-369, 1995

White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia. Leukemia and Lymphoma 48(8): 1561-1568, 2007